Abstract
Although by this stage the utility of alprostadil in erectile dysfunction (ED) was well known and the drug was widely used, there had been no long-term analysis of efficacy and safety. This trial showed that efficacy was maintained over a 4-year period and that there was no tachyphylaxis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
7.1 Key Trial References
7.1.1 Major Publication
Porst H, Buvat J, et al. Intracavernous Alprostadil Alfadex — an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 10:225–231, 1998.
7.1.2 Other Important Publications
The long-term safety of alprostadil (prostaglandin — E1) in patients with erectile dysfunction. The European Alprostadil Study Group. Br J Urol 82(4):538–543, 1998.
Purvis K, Egdetveit I, Christiansen E. Intracavernosal therapy for erectile failure — impact of treatment and reasons for drop-out and dissatisfaction. Int J Impot Res 11(5):287–299, 1999.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). An Elegant Long-Term Trial Assessing the Clinical Profile of Intracavernosal Prostaglandin E1 (Alprostadil). In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_7
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)